"Pharmacovigilance Challenges in Personalized Medicine and Pharmacogenomics"

[1]Anand N. Deshmukh, [2]Saurabh S. Shinde, [3]Prof U.R Bansod, [4]Prof A.V Aswar, [1,2] Student, [3,4]Department of Pharmacology, Dr. Rajendra Gode College of Pharmacy, Amravati-444602, Maharashtra (INDIA).

Abstract: Personalized medicine and pharmacogenomics is a paradigm shift in the healthcare industry where treatment choices are being made based on the genetic composition of an individual, and the environment and lifestyle. Although these methods will yield better effectiveness and fewer adverse drug reactions (ADRs), they are also quite challenging to the pharmacovigilance systems. The conventional post-marketing surveillance systems and ADR reporting systems are not well-prepared to deal with the complexity of the genetic guided therapies. The present review addresses the new trends of concern in pharmacovigilance with personalized medicine that consist of genetic variations, rare adverse drug reactions, lack of clinical trial information, data integration, regulatory challenges, and ethical concerns. Mechanisms to address these challenges with the help of advanced monitoring, real-world evidence (RWE), bioinformatics, and patient-centric are also addressed.

***Keywords*:** Pharmacovigilance, Personalized Medicine, Pharmacogenomics, Adverse Drug Reactions, Genetic Variability, Real-World Evidence, Drug Safety.

Introduction

Patient safety relies on the science and activities of pharmacovigilance identified to detect, evaluate, comprehend, and mitigate adverse drug reactions (ADRs) and other problems related to drugs. Conventionally, pharmacovigilance has been aimed at population-based surveillance (implicitly supported by clinical trials, post-marketing surveillance and spontaneous reporting systems) to detect and mitigate drug safety issues.

The future of drug therapy is changing radically with the emergence of personalized medicine and pharmacogenomics. Personalized medicine seeks to optimize their therapy approach to each specific patient by considering the genetic, environmental, lifestyle factors whereas pharmacogenomics evaluates the impact of genetic variations on drug response. These methods can deliver improved efficacy, reduced ADRs, and increase dosing optimality and represents a shift of the traditional model of therapeutics customization as a one-size-fit-all treatment to precision therapeutics.

Nevertheless, the process of such transition creates special difficulties to pharmacovigilance. Personalized medicine ADRs can be infrequent, genotype-specific, or limited to small subpopulations and are more difficult to identify by conventional monitoring methods. In addition, incorporating genomic, electronic health records (EHRs) and real-world evidence (RWE) into pharmacovigilance models create technical, ethical, and regulatory challenges. The need to maintain the privacy of data, standardization and equal access further complicates matters.

In this review, the author concentrates on the new challenges brought out by pharmacovigilance in the era of personalized medicine and pharmacogenomics, and the problem of genetic variability, insufficient clinical trial data, data management, ethical concerns, and regulatory deficiencies are highlighted. In addition, possible solutions to the mentioned challenges such as the use of advanced monitoring technologies, patient-centricity, and international regulatory harmonization are also addressed with a focus on the changing role of pharmacovigilance in precision healthcare.



Figure 01: Pharmacovigilance Challenges in Personalized Medicine and Pharmacogenomics.

Personalized Medicine and Pharmacogenomics

Personalized medicine is a medical practice that tailors healthcare choices, therapeutic procedures and interventions based on the unique attributes of the different patients. Instead of a one-size-fits-all approach, personalized medicine takes into account genetic, environmental, and lifestyle variables that contribute to susceptibility to disease and attempts to respond to the therapy. In this context, pharmacogenomics is at the center stage as it analyzes the impact of the genetic variations on the drug absorption, distribution, metabolism, excretion and pharmacodynamic response. Personalized medicine has an improved scope to drug development, clinical prescription, and post-marketing surveillance to maximize efficacy and reduce adverse effects.

Genetic determinants of drug response include drug-metabolizing enzyme, drug transporter and drug target polymorphisms as the main ones. The difference in cytochrome P450 enzymes e.g. CYP2D6, CYP2C9 and CYP2C19 may cause poor, intermediate or ultra-rapid metabolism of drugs and this causes changes in plasma drug concentration and different clinical effects. In the same manner, variations in drug transporters such as P-glycoprotein, receptors or enzyme to which drugs bind, can also vary with genetic variation to determine therapeutic effectiveness, as well as the risk of drug-induced adverse reactions. Some human leukocyte antigen

(HLA) types have been linked with severe reactions of immune mediation against drugs, which adds weight to genetic screening in drug safety.

Pharmacogenomics has proved to be very useful in enhancing patient care in a clinical setting. Pharmacogenomic assays can assist in drug choice and dose optimization, minimize the rate of adverse medicine reactions, and improve treatment results. It is especially useful in such a field as oncology, cardiology, psychiatry, and infectious diseases with a strong variability of drug responses. Through its ability to help the process of therapy be more precise and safer, personalized medicine does not only contribute to being more effective clinically but also allows assessing the benefit-risk more effectively, and this point is what makes it necessary to incorporate it into pharmacovigilance practices.

Role of Pharmacovigilance in Personalized Therapy

The conventional methods of pharmacovigilance are mainly population based and aim at identifying and assessing adverse drug reactions via clinical trials, spontaneous reporting schemes, post-marketing monitoring and observational research. These techniques strive to isolate indicators of safety through the examination of information obtained through large and diverse populations of patients. Although useful in identifying common and some rare undesirable effects, the conventional pharmacovigilance is not usually able to explain interindividual differences in drug reaction and may miss the possibility of adverse reactions only appearing in certain genetic subgroups.

As a personalized therapy becomes more and more popular, individualized safety monitoring becomes more demanded. Personalized medicine divides the patient population into smaller, genetically characterized subpopulations, in which a disease reaction to the adverse effects of a drug can be uncommon, yet clinically relevant. Pharmacovigilance systems should thus adapt to the requirements of capturing patient unique aspects such as genetic aspect to facilitate early identification of effects of the genotype on safety. Personalized safety observation contributes to the prevention of risks in advance, makes it possible to use specific measures aimed at reducing risk, and improves the formation of therapeutic decisions in a patient.

When personalized medicine is incorporated in pharmacovigilance, the effect on the benefit-risk assessment is immense. Through the integration of pharmacogenomic findings, pharmacovigilance can be conducted on a less generalized risk scale to a subgroup of observations of drug safety and efficacy. This method enables the better labelling of the drugs, the optimal dosage, and the more informed clinical guidelines. Finally, personalized pharmacovigilance enhances the evaluation of the benefits and risks by integrating the analysis of drug safety with the concept of precision medicine, which will result in safer and more efficient therapeutic effects.

Pharmacovigilance Challenges in Pharmacogenomics

Small and genetically defined populations of patients can also be taken as one of the key issues of pharmacovigilance in the pharmacogenomics. Personalized medicine classifies patients in terms of genetic attributes and makes them smaller subgroups, which might not be sufficiently represented in pre-marketing clinical trials. This small sample size compromises statistical power to identify safety signals and risks that genotype-related adverse drugs reactions will remain undetected until common use in clinical practice.

Another problem is the identification of rare and genotype-specific adverse drug reactions (ADRs). The severe or life-threatening ADRs have been linked to certain genetic variants, although they can be infrequent and only exhibited by individuals who have a particular allele. The traditional pharmacovigilance methods, where the focus is on spontaneous reporting, might not reveal enough information to define definite genotype-ADR relationships and promptly identify significant dangers.

Another weakness is that pharmacogenomic data are not provided in ADR reporting systems. The available pharmacovigilance databases cannot easily correlate adverse events with genetic factors and most of them do not regularly capture or encompass genetic data. Lack of standard fields to harbor pharmacogenomic data limits the ability to draw meaningful signals, evaluate causality and derive sense of individualized safety data.

The problem of data fragmentation and interoperability is also an issue that prevents effective pharmacovigilance in pharmacogenomics. Genetic data, clinical records, and pharmacovigilance databases are frequently in different systems, which do not have harmonized standards and interoperability. This fragmentation does not allow a thorough analysis of data and does not allow effective incorporation of pharmacogenomic information into regular safety surveillance.

The questions of ethics, law, and privacy are also the most crucial issues of genetic data usage in the context of pharmacovigilance. Genetic information is very sensitive, and the issues associated with genetic information are patient confidentiality, informed consent, data ownership and misuse. It needs strong ethical standards and legal protection to be sure that data management is secure and to permit valuable safety surveillance.

Lastly, some regulatory and policy issues make the implementation of pharmacogenomics in pharmacovigilance difficult. There were few regulations in place that were specific to standard medicines, and these regulations might be ineffective in solving genotype-specific safety concerns. The regulatory bodies struggle with the definition of submission requirements of pharmacogenomic data, changes in the drug label, and risk management strategies in personalized treatments. The solution to these issues is critical in the formulation of adaptive pharmacovigilance systems that are capable of facilitating pharmacogenomic-based clinical practice.



Figure 02 : Key Pharmacovigilance Challenges in Pharmacogenomics.

Limitations of Conventional Pharmacovigilance Systems

The traditional pharmacovigilance systems rely on the population-wide surveillance method of drug safety evaluation based on aggregated data of various groups of patients. As this method is good in detecting common adverse drug reactions, it is limited by nature in detecting safety issues that would happen only in certain subpopulations. Population based surveillance does not appreciate interindividual variation in response to drugs, especially variation based on genetic diversity, thus giving an incomplete picture of the safety of the drug in personal therapeutic environment.

Skewed safety reports and inadequate safety information contribute to the weakness of traditional pharmacovigilance systems. The post-marketing surveillance is based on the system of spontaneous reporting; and is therefore based on voluntary surveillance by health care professionals and patients. Consequently, a large number of adverse drug reactions are not reported at all or reported inadequately. Such underreporting inhibits correct signal identification, slows the potential risks identification, and impairs the overall safety assessment, particularly of rare or late adverse reactions.

The second severe shortcoming is the lack of genetic background in safety signal detection. Pharmacogenomic information is not always present in the traditional pharmacovigilance databases, and there is not an easy way to correlate adverse drug reaction with particular genetic variants. Assessment of causality cannot be done without genetic data and the safety risk or threat associated with a particular genotype might not be identified. This hinders genetic integration necessary to enable conventional pharmacovigilance systems to facilitate precision medicine, and more adaptive and genomics-informed approaches to safety monitoring are required.

Emerging Approaches and Solutions

The drawbacks of traditional pharmacovigilance systems have led to the emergence of new systems and methods based on real-world evidence, using advanced analytical systems to aid drug safety in personalized medicine. Real-world evidence (RWE), which the authors obtained through electronic health records, insurance claims, patient registries, and observational studies, offers useful information regarding the use and safety of the drug used in everyday clinical practice. In conjunction with big data analytics, RWE will allow the analysis of large and heterogeneous datasets, which will permit the detection of rare, delayed, and genotype-specific adverse drug reactions that are unlikely to be identified in controlled clinical trials.

Cardiogenomic integration Electronic health record (EHR) and genomic database integration is an essential breakthrough in pharmacovigilance. A connection between clinical outcomes, medication history, and pharmacogenomic data could be used to assess the safety of the drugs in individuals at a more comprehensive level. This type of integration enhances the completeness of data, longitudinal tracking, and the establishment of correlation between genetic variants and adverse drugs reactions. To do everything possible to make this approach effective, it is necessary to standardize the data format and interoperability of systems.

Application of artificial intelligence (AI) and machine learning (ML) is being used more and more to improve signal detection in pharmacovigilance. These technologies have the capability of processing high dimensional, complicated data and finding patterns that might have been hidden in traditional statistical model. Artificial intelligence-based algorithms have the potential to enhance the safety signal detection accuracy and timeliness, aid in the predictive risk assessment, and aid in recognizing genotype-specific safety issues during personalized therapies.

The active surveillance systems and patient registries are also crucial in enhancing pharmacovigilance in pharmacogenomics. In contrast to passive reporting systems, active surveillance is proactive and actively oversees predetermined patient groups, which makes it possible to independently gather and follow up the information. Pharmacogenomic-specific registry offers useful real-world safety information about genetically defined subgroups, which can be used in making early predictions about adverse events that do not reliant on data miners but on risk reduction strategies. Collectively, the above emerging strategies form a healthier, flexible, and patient-oriented pharmacovigilance system appropriate to personalized medicine.

Figure 03: Emerging Strategies to Strengthen Pharmacovigilance in Personalized Medicine.

Role of Regulatory Authorities

In the environment of personalized medicine and pharmacogenomics, regulatory bodies are the key participants in determining pharmacovigilance activities and drug safety. On an international scale, pharmacovigilance solutions, post-marketing surveillance, and risk management practices are directed by such agencies as the World Health Organization (WHO), the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA). There is growing recognition that these agencies should include pharmacogenomic information in their regulatory decision-making process and efforts to enhance the overall benefit-risk assessment of medicines and also promote patient safety in a wide range of populations.

The pharmacogenomic biomarkers have gained a significant note in drug development and regulatory approves. Regulatory bodies are promoting the detection and confirmation of the genomic biomarkers which may predict the medication response, efficacy, or likelihood of adverse drug response. The drug labels usually contain such biomarkers in order to direct healthcare providers to choose the right therapy or dose schedule of a particular subgroup of a patient. Labelling information based on pharmacogenomics can be in the form of recommendation to genetic testing, dose changes, contraindications, or warning of patients with certain genetic variants, hence enhancing safer and more effective use of drugs.

Moving forward, the next generation of regulatory structures should be flexible to the changing nature of personalized medicine. This involves putting in place clear specifications of how pharmacogenomic information should be collected, reported and assessed with regard to the pharmacovigilance systems. The regulators also have the mandate to foster international standards harmonization, facilitate the incorporation of real-world evidence, and discuss ethical and privacy issues that genetic data entail. Through enhanced

cooperation of stakeholders and adoption of innovative regulatory strategies, the officials can enhance the pharmacovigilance systems and enable the safe use of pharmacogenomics in clinical practice.

Future Perspectives

The future of pharmacovigilance is the shift to precision pharmacovigilance, in which drug safety monitoring is oriented towards the principles of personalized medicine. Precision pharmacovigilance combines pharmacogenomic information, clinical features and real-world data to help in more precise detection of safety hazards in particular subsets of patients. This method will enable the early identification of genotype-specific drug adverse reactions and allow tailored risk mitigation plans by departing with population-based assessments, thus enhancing therapeutic outcomes.

The patient-centred safety monitoring is likely to gain greater significance in the subsequent pharmacovigilance systems. Patients can be empowered by allowing them to play an active role in reporting adverse drug reactions using digital platforms, mobile health applications, and patient registries to improve data quality and timeliness. The clinical and genetic data with patient-reported outcomes will give a better picture of the drug safety and tolerability in real life, especially in personalized therapies.

The introduction of pharmacogenomics as a pharmacovigilance approach will require capacity building and training of healthcare professionals to achieve success. Medical professionals should have sufficient knowledge and skills on how to read pharmacogenomic data, identify drug reaction that are genotype-related and how to report safety data safely. The ongoing education, training initiatives, and interdisciplinary collaboration will play a paramount role in enhancing the pharmacovigilance systems and policing safe and effective use of individualized medicines in clinical practice.

Conclusion

Pharmacovigilance has been a pillar of patient safety and its significance has increased considerably as personalized medicine and pharmacogenomics has developed. Although pharmacogenomic-guided therapy has significant advantages in enhancing drug efficacy and decreasing adverse drug reactions, it poses a new challenge to the traditional population-based pharmacovigilance systems. The variability in drug response that is genetically predetermined, infrequent and subgroup-specific adverse reactions, as well as a limited integration of genomic information into the current system of monitoring drug safety, suggest that adaptive methods of drug safety surveillance are necessary.

To overcome these issues, there is a need to switch to more integrated and innovative pharmacovigilance models that embrace real-world evidence and electronic health records, pharmacogenomic data, and more sophisticated analytic tools including artificial intelligence and machine learning. Enhancement of regulatory mechanisms, appropriate ethical management of genetic information and international harmonization is also essential to facilitate successful safety surveillance in personalized medicine.

To sum up, the development of precision pharmacovigilance is a viable direction towards reconciliation of drug safety assessment and personalized drug treatment policies. By implementing collaborative actions by regulatory bodies, medical practitioners, scientists, and patients, pharmacovigilance systems would be reformed to aid in the safe, efficient, and responsible adoption of pharmacogenomics, which would eventually result in improved patient outcomes and improved personalized healthcare.

References

1. World Health Organization. **The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products.** WHO Press; 2002.
2. Edwards IR, Aronson JK. **Adverse drug reactions: definitions, diagnosis, and management.** *The Lancet.* 2000;356(9237):1255–1259.

3. Pirmohamed M, et al. **Adverse drug reactions as cause of admission to hospital: prospective analysis.** *BMJ.* 2004;329:15–19.
4. Lesko LJ, Schmidt S. **Individualization of drug therapy: history, present state, and opportunities for the future.** *Clinical Pharmacology & Therapeutics.* 2012;92(4):458–466.
5. Weinshilboum R, Wang L. **Pharmacogenomics: bench to bedside.** *Nature Reviews Drug Discovery.* 2004;3:739–748.
6. Phillips KA, et al. **Potential role of pharmacogenomics in reducing adverse drug reactions.** *JAMA.* 2001;286(18):2270–2279.
7. Pirmohamed M. **Personalized pharmacogenomics: predicting efficacy and adverse drug reactions.** *Annual Review of Genomics and Human Genetics.* 2014;15:349–370.
8. Wilke RA, et al. **The clinical application of pharmacogenomics.** *Trends in Pharmacological Sciences.* 2007;28(4):182–188.
9. Evans WE, McLeod HL. **Pharmacogenomics—drug disposition, drug targets, and side effects.** *New England Journal of Medicine.* 2003;348:538–549.
10. FDA. **Guidance for Industry: Pharmacogenomic Data Submissions.** U.S. Food and Drug Administration; 2005.
11. European Medicines Agency (EMA). **Guideline on good pharmacovigilance practices (GVP).** EMA; 2012.
12. Kalra D, et al. **Ethical, legal, and social issues in pharmacogenomics.** *Pharmacogenomics Journal.* 2010;10:453–458.
13. Hood L, Friend SH. **Predictive, personalized, preventive, participatory (P4) cancer medicine.** *Nature Reviews Clinical Oncology.* 2011;8:184–187.
14. Ingelman-Sundberg M. **Pharmacogenetic biomarkers as tools for improved drug therapy.** *Trends in Pharmacological Sciences.* 2008;29(7):342–349.
15. FDA. **Table of Pharmacogenomic Biomarkers in Drug Labeling.** U.S. Food and Drug Administration.
16. Hauben M, Zhou X. **Quantitative methods in pharmacovigilance: focus on signal detection.** *Drug Safety.* 2003;26(3):159–186.
17. Wise L, et al. **Real-world evidence and pharmacovigilance.** *Pharmacoepidemiology and Drug Safety.* 2019;28(7):889–897.
18. Rajkomar A, et al. **Machine learning in medicine.** *New England Journal of Medicine.* 2019;380:1347–1358.
19. Arlett P, et al. **Pharmacovigilance in the era of personalized medicine.** *Drug Safety.* 2014;37(11):867–875.
20. Meyer UA. **Pharmacogenetics and adverse drug reactions.** *The Lancet.* 2000;356(9242):1667–1671.